Evidence map›Paper›PMID 16900364›Full record

ReviewDer Internist2006

[Stage appropriate therapy for COPD].

H Hamm

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Der Internist, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

H HammAkutkrankenhaus u. Rehabilitationsklinik für Atemwegs-und Tumorerkrankungen, Asklepios Nordseeklinik, Westerland/Sylt. h.hamm@asklepios.com
Asklepios Kliniken Hamburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment of chronic obstructive pulmonary disease (COPD) has improved substantially over recent years, and is increasingly based on evidence from prospective studies. Cessation of smoking is the most important and effective single measure which can be taken. In the early stages, intensive measures for nicotine withdrawal should be taken to prevent the catastrophic effects of disease progression. Pharmacological treatment of COPD in the earlier stages (0-II) should be symptom oriented. Asymptomatic patients at these stages do not require permanent pharmacotherapy. From Stage II, COPD patients benefit from pulmonary rehabilitation programs. Patients with stages III and IV should usually be put on long-term corticosteroid inhalation, preferably in combination with long-acting bronchodilators. Systemic corticosteroids, even at low doses, are not indicated. They are useful only for the short-term treatment of acute exacerbations. These treatment modalities improve the quality of life and morbidity of COPD patients. They also decrease exacerbations and hospitalization rates, which should help to reduce mortality due to this important disease.

Indexed as

Administration, InhalationAdministration, OralAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsAdrenergic beta-AgonistsBronchodilator AgentsCholinergic AntagonistsCombined Modality TherapyEvidence-Based MedicineExercise TherapyExpectorantsHumansOxygen Inhalation TherapyPulmonary Disease, Chronic ObstructiveSmoking CessationTheophyllineAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsAdrenergic beta-AgonistsBronchodilator AgentsCholinergic AntagonistsExpectorantsTheophylline

Identifiers

PMID16900364
OpenAlexW174280428

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.